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Summary The effect of cancer cachexia on the oxidative metabolism of lipids has been studied in mice
transplanted either with the MAC16 adenocarcinoma, which induces profound loss of host body weight and
depletion of lipid stores, or the MAC13 adenocarcinoma, which is of the same histological type, but which
grows without an effect on host body weight or lipid stores. While oxidation ofD-[U-'4C]glucose did not differ
between animals bearing tumours of either type and non-tumour bearing controls, oxidation of [1-'4C]triolein
administered by intragastric intubation was significantly (P<0.05) higher in animals bearing the MAC16
tumour than in either non tumour-bearing controls or in animals bearing the MAC13 tumour. Intestinal
absorption of [4C]lipid was significantly (P<0.05) reduced in animals bearing the MAC13 tumour when
compared with either non tumour-bearing animals or MAC16 tumour-bearing animals, but was not signi-
ficantly different in the latter two groups. The level of labelled lipids in heart and adipose tissue after an oral
['4C]lipid load was significantly lower in animals bearing the MAC16 tumour compared with the other two
groups. The level of tumour lipids was also higher in the MAC16 than in the MAC13 tumour after both an
oral ['4C]lipid load or by direct injection of [U-'4CJpalmitate complexed to albumin into epididymal fat pads.
Oxidation of [U-'4C]palmitate was also significantly enhanced in liver and heart homogenates from animals
bearing the MAC16 tumour. These results suggest that in cachectic tumour-bearing animals mobilisation of
body lipids is accompanied by an increased utilisation.
Depletion of host fat stores is a common finding in cancer
cachexia. We (Beck & Tisdale, 1987) and others (Kitada et
al., 1981; Masuno et al., 1981) have attributed this loss of
body fat, at least in part, to a circulatory lipid mobilising
factor derived from the tumour cells (Beck & Tisdale, 1991).
Although anorexia is common in cancer, loss of carcass fat
cannot be attributed to a decreased caloric intake alone, since
pair-fed rodents have been shown not to lose as much fat as
tumour-bearing animals (Lundholm et al., 1981). In some
experimental models of cachexia, loss of host adipose tissue
is associated with hyperlipidemia (Devereux et al., 1984),
although in the MAC16 model of cachexia, utilised in this
study, plasma levels of both non esterified fatty acids
(NEFA) and triacylglycerols have been shown to be reduced
(Mahoney et al., 1988), possibly due to an elevated level of
lipoprotein lipase in skeletal muscle (Briddon et al., 1991).
This suggests that the liberated fatty acids are rapidly
oxidised in this model. Changes in fuel utilisation have also
been reported in cancer patients with lipid sources predomin-
ating (Warnold et al., 1978).
In addition to host requirements the NEFA liberated dur-
ing the cachectic process may also be required to maintain
tumour growth. Nutritional conditions favouring mobilisa-
tion of host adipose tissue such as during an acute fast
(Sauer & Dauchy, 1987a) and acute streptozotocin-induced
diabetes (Sauer & Dauchy, 1987b) have been shown to stimu-
late tumour growth, suggesting that tumour growth in vivo
may be limited by substances present in host fat stores. This
view is strengthened by the observation that inhibition of
host fat mobilisation in cancer cachexia is also associated
with an inhibition of tumour growth (Tisdale & Beck, 1991).
The present study documents changes of host lipid metabo-
lism in a murine model of cachexia, the MAC16 colon
adenocarcinoma. In comparison with other models this
tumour induces profound weight loss in host animals with
relatively small tumour burdens (>0.1% of host body
weight) and without an alteration in food and water intake
(Beck & Tisdale, 1987) and is useful for studying the meta-
bolic effects of the tumour on the host in the absence of
anorexia. In addition tumours of the same histological type
are available which grow without an accompanying cachexia
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(e.g. MAC13), which can be utilised as a comparison to
determine metabolic changes specific to the cachectic process.
Materials and methods
Pure strain NMRI mice bred in our own colony were fed a
rat and mouse breeding diet (Pilsbury, Birmingham, UK)
and water ad libitum. Fragments of either the MAC16 or
MAC13 tumour were implanted into the flank of male
NMRI mice (starting weight 24-26 g) by means of a trocar,
as described (Bibby et al., 1987). Animals bearing the
MAC16 tumour developed weight loss 10-12 days following
transplantation (average tumour weight 200 mg) and were
used when the weight loss averaged 2 to 4 g. Animals bearing
the MAC13 tumour were used 10-12 days following tumour
transplantation when the average tumour weight was similar
to that in animals bearing the MAC16 tumour. Non tumour-
bearing mice of the same weight (26 g) were used as controls.
The daily food intake in animals bearing the MAC16 tumour
(15.1 ± 0.6 Kcal) did not differ from that of non tumour-
bearing controls (15.3 ± 0.3 Kcal), while in animals bearing
the MAC13 tumour, the daily food intake (16.4 ± 0.3 Kcal)
was significantly (P<0.01) increased.
Production Of 4C02from D-[U-`4C]glucose
Male NMRI mice bearing either the MAC16 tumour with
weight loss (2-4 g), the MAC13 tumour or non tumour-
bearing controls were injected i.v. with 50lsCi kg-' of D[U-
'4C]glucose (sp.act. 273 mCi mmol'l) (Amersham Interna-
tional, Amersham, UK) and were placed in airtight metabolic
cages with the entry air being pumped through calcium car-
bonate (solid) to absorb any CO2. Metabolically produced
4C02 was trapped in glass test-tubes containing 20 ml of a
mixture of ethanolamine: ethoxyethanol (1:4). At specified
time intervals samples (0.5 ml) were removed and the radio-
activity was determined directly in Optiphase scintillation
fluid (FSA Laboratory Supplies, Loughborough, UK) using
a Packard Tri-Carb 2000CA liquid scintillation analyser.
Lipid oxidation and tissue lipid accumulation
The absorption, accumulation and oxidation of an oral dose
of ['4C]lipid was determined using the method of Oller do
Nascinmento and Williamson (1986). [1-_4C]Triolein (0.33 pCi;
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sp.act. 114 mCi mmol ') (Amersham International, Amer-
sham, Bucks, UK) together with 70 mg of non-labelled trio-
lein was administered enterally by gastric intubation without
anaesthesia to male NRMI mice bearing the MAC16 tumour
and with weight loss, the MAC13 tumour or non tumour-
bearing controls, with minimal stress. Immediately after
administration animals were placed in airtight metabolic
cages and expired CO2 was collected for 5 h as described
above. After 5 h, animals were anaesthetised and blood was
collected by cardiac puncture. The complete gastrointestinal
tract was removed and homogenised in 5 ml of 3% (w/v)
HC104. Lipids were extracted from organs and blood by the
method of Stansbie et al. (1976). The extracted fatty acids
were dissolved in Optiphase scintillation fluid and the radio-
activity determined as above. Triolein absorption was
calculated by subtracting the total gastrointestinal tract
radioactivity from that administered.
Lipidmobilisationfrom direct injection oftracer intofat pads
Serum was collected from male NRMI mice fed a 60%
glucose: 40% rat and mouse breeding diet to lower their
plasma NEFA level (Lyon et al., 1988). [U-_4C]Palmitic acid
(501.Ci sp.act. 828 mCi mmol ') was dissolved in 0.5 ml of
30% (w/v) KOH and the resultant soap was dried under
nitrogen. The dried soap was dissolved in 2001l of 0.9%
(w/v) NaCl and heated to 70°C until a clear solution was
obtained. The soap solution was added dropwise to 200 pJ of
the serum, the volume of the serum being minimised so that
in the final complex, the molar ratio of NEFA to serum
albumin was approximately 7:1 (Lyon et al., 1988). A few
drops of Evans Blue dye was added to the tracer to aid visual
inspection after injection to mice. Animals were anaesthetised
using a mixture of halothane, oxygen and nitrous oxide
(halothane 2.5%, oxygen 0.5 ml min ', N2O 0.7 ml min'). A
small incision was made in the lower abdomen and the left
epididymal fat pad was gently externalised using a saline
wetted probe. With the aid of the magnifying glass, 2ptl of
the tracer: albumin complex was injected into the fat pad
using a Hamilton microsyringe. The fat pad was examined to
ensure that no leakage of tracer had occurred. For time
points beyond time zero the fat pad was gently returned to
the abdominal cavity and the wound was clipped. At speci-
fied time points animals were sacrificed, tissues were removed
and the concentration of labelled lipids determined by the
methods of Stansbie et al. (1976).
Oxidation ofpalmitate by tumour and host tissues
Tissues were homogenised in 250 mM mannitol (500 mg tis-
sue per ml) at 4°C and a portion of the homogenate corre-
sponding to 100 mg of tissue was routinely incubated for up
to 20 min at 37°C in a total volume of 2 ml containing
50 mm phosphate buffer, pH 7.4, 4mM ATP, 95 mM KCI,
3 mM MgSO4, 0.1 mM sodium [U-"4C]palmitate (sp.act. 1 ttCi
jtmole 1), 1 mM NAD, 40 mg albumin and 1 mg cytochrome
C. The assay was terminated by the addition of 0.5 ml of
10% perchloric acid and the "4CO2 was trapped in centre
wells containing 0.3 ml of 0.3 M NaOH. The water soluble
products of palmitate oxidation were determined by extract-
ing the radioactive lipid with four washes of petroleum and
diethyl ether (95:2) (2 ml ml-' of incubation medium). Radio-
activity was determined in Optiphase scintillation fluid as
above.
Statistical analysis
Differences between groups were determined by one way
analysis of variance followed by Tukey's test.
Results
In order to minimise variations in the specific activity of
blood glucose a bolus injection of D-[U-'4C]glucose was
administered i.v. on a weight basis and production of "'CO2
was measured over a short time period (10 min). Using such
a protocol, production of "'CO2 did not differ significantly
between animals bearing either the MAC16 or MAC13
tumours and non tumour-bearing controls animals (Figure
1).
The ability of the animals to deal with administered lipid
was investigated using [1-"'C]triolein, which was given by
intragastric intubation, and the absorption over a 5 h period
was monitored (Table I). While fat absorption in animals
bearing the MAC16 tumour was not significantly different
from that in non tumour-bearing controls, animals bearing
the MAC13 tumour had a small, but significantly (P<0.05)
reduced fat absorption over the 5 h period. This suggests that
mobilisation of the host lipid stores in cancer cachexia (Beck
& Tisdale, 1987; 1991) is not due to defective lipid absorp-
tion, but that the tumour-bearing state may restrict gut
function irrespective of the development of weight loss. The
rate of oxidation of [1-1'C]triolein to '4CO2 for the three
groups is shown in Figure 2. At all time points examined
animals bearing the MAC16 tumour had a higher excretion
level of "'CO2 than either non tumour-bearing animals or
animals bearing the MAC13 tumour. In contrast, animals
bearing the MAC13 tumour oxidised [1-"'C]triolein to 14CO2
at a rate not significantly different from that in non tumour-
bearing animals.
The pattern of distribution of labelled lipid between
tumour and host organs also differed between the three
groups (Table I). Thus heart and adipose labelled lipids
together with total plasma lipids were significantly reduced in
animals bearing the MAC16 tumour when compared either
with animals bearing the MAC13 tumour or non tumour-
bearing controls. The level of labelling of brain and adipose
lipids was lower in both tumour-bearing states. There was no
difference in urinary of faecal output in the three groups.
In order to understand further the path taken by lipids
from host adipose tissue in the cachectic animal [U-"'C]
palmitic acid complexed to albumin was directly injected into
the epididymal fat pads. Lyon et al. (1988) have previously
shown that triacylglycerol fatty acids in the heterogeneously
labelled adipocytes reflected the behaviour of the respective
fat pad triacylglycerol fatty acid. The rate of disappearance
of triacylglycerol fatty acid radioactivity in non tumour-
bearing animals and animals transplanted with the MAC16
and MAC13 tumours is shown in Figure 3. The recovery of
the labelled palmitate at zero time was approximately 90%
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Figure 1 Production Of '4C02 from D-[U-"'C]glucose by non
tumour-bearing animals (0) and in animals bearing either the
MAC13 (A) or MAC16 (M) tumours. Results are expressed as
means±sem. for eight animals per group.LIPID METABOLISM IN CANCER CACHEXIA 59
Table I Effects oftumour type on the absorption and metabolic fate of orally administered [1-'4C]triolein
Absorption Tissue ["Cilipid accumulation (% absorbed dose/Shlg)
['14Clipid % Gastro-
administration cnemius
Group dose/S h Liver Heart Brain muscle Kidney Adipose Plasma Tumour
Control 96.1±0.8 1.19±0.35 0.51±0.14 0.11±0.04 0.12±0.02 0.64±0.11 0.84+0.13 0.06 ±0.02 -
MAC16 94.0±0.9 0.98±0.14 0.26+0.05b,d0.053±0.007a 0.10± 0.03 0.63±0.11 0.22+0.03b,c 0.037±0.008a 0.16±0.08
MAC13 86.4±2.8a 1.29±0.37 0.48±0.04 0.043 ±0.007a 0.13±0.02 0.56±0.04 0.52±0.1ia 0.049±0.008 0.09±0.01
Allgroupsofanimalswerefed adlibitum. Theresultsaremeanvalues±s.e.m. forsixanimals pergroup. Values thataresignificantly differentfrom
controlsvaluesareindicatedbyap<0.05, bp<0.001. ValuesforMAC16tumour-bearinganimalsthataresignificantlydifferentbypaired t-testfrom
MAC13 tumour-bearing animals are indicated by CP<0.05; dp<0.005.
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Figure 2 Production of "4CO2 from [1-_4C]triolein administered
enterally by gastric intubation to non tumour-bearing animals
(0) and to animals bearing either the MAC13 (A) or MAC16
(U) tumours. Results are expressed as mean±s.e.m. for six
animals per group. Differences from controls are expressed as a,
P<0.05; b, <0.01; c, P<0.005 and differences between MAC16
and MAC13 tumour-bearing animals are d, P<0.005 and e,
P<0.001.
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Figure 3 Rate of loss of radioactivity from [U-"'C]palmitate
labelled epididymal fat pads of non tumour-bearing animals (0)
and animals bearing either the MAC16 (E) or MAC13 (A)
tumours. Results are expressed as mean±s.e.m. for six animals
per group per time point and differences from non tumour-
bearing animals are shown as a, P<0.05 and between MAC16
and MAC13 tumour-bearing animals as e, P<0.05.
showing that very little leakage to other sites had occurred.
While the amount of labelled lipid in the fat pads of control
and MAC13 tumour-bearing animals did not change apprec-
iably during the 60 min period after injection, there was a
reduction of approximately 50% in animals bearing the
MAC16 tumour. The appearance of labelled lipids in tumour
and host organs 60 min after injection of the labelled pal-
mitate is shown in Table II. Incorporation of radioactivity
into liver at the 1 h time point was lower in both sets of
tumour-bearing animals than in non tumour-bearing controls
and incorporation into brain was higher, while incorporation
into muscle was significantly greater in animals bearing the
MAC16 tumour than in either control animals or those
bearing the MAC13 tumour. The level of ['4C]lipid was
significantly (P<0.001) higher in the MAC16 tumour than
in the MAC13 tumour. This suggests utilisation of adipose
tissue lipids by both host organs and tumour in cachectic
tumour-bearing animals.
In order to investigate utilisation of lipid by individual
organs and tumour, the rates of oxidation of [U-'4C]palmi-
tate to "'CO2 and water-soluble products was determined in
homogenates. The rate of '4CO2 production was linear for a
20min period. The results presented in Table III show the
major organ consuming palmitate was the liver. There was a
2-fold increase in conversion of [U-"'C]palmitate to "'CO2 in
liver and heart of animals bearing the MAC16 tumour and a
more than 2-fold increase in muscle from animals bearing
both the MAC16 and MAC13 tumours. Respiration from
palmitate was low in both tumours, but was significantly
higher in the MAC16 than in the MAC13 tumour. Conver-
sion of palmitate to water-soluble products was also signi-
ficantly enhanced in hearts from MAC16 tumour-bearing
animals when compared with either controls or MAC13
tumour-bearing animals and was significantly enhanced in
muscle of animals bearing both the MAC16 and MAC13
tumours. These results confirm that lipid oxidation was
significantly higher in cachectic animals bearing the MAC16
tumour.
Discussion
In view of its high calorific value, fat is an important fuel
source when the metabolic demands of an organism are high,
Table II Effect oftumour type on the distribution of[U-`'C]palmitate
60 min after direct injection into epididymal adipose tissue
Organ "C lipid accumulation (% ofinjected dose)
Group Musclea Liver Brain Tumour
Control 1.0±0.1 3.9±0.6 0.5±0.1
MAC16 1.7±0.1Ce 2.1+0.4b 1.7±0.Id 1.7±0.le
MAC13 0.8±0.1 1.7±0.6b 1.5±0.lc 0.1±0.1
aCombined values for the thigh plus gastrocnemius muscle from the
left leg. Values represent '4C-labelled lipid (percentage ofinjected dose)
per organ 60 min after direct injection of [U-_4C]palmitate into
epidiymal adipose tissue. The results are mean values±s.e.m. for six
animals per group. Values that are significantly different from control
values are indicated bybp<0.05; cP<0.005; cP<0.001 and values for
MAC16 tumour-bearing animals that are significantly different from
MAC13 tumour-bearing animals are indicated by CP< 0.001.60 H.D. MULLIGAN et al.
Table III Utilisation of [U-'4C]palmitate by tumour and host organs
Tissue ['4C]palmitate conversion (nmolegh)d
Control MAC13 MACJ6
Organ 14CO2 soluble Total "4CO2 soluble Total 1CO2 soluble Total
Liver 40.2± 5.4 448±34 488±34 41.6±7.4 514±10 560±20 112.6±8.4b 466±34 572±40
Heart 21±1 79±9 90±7 20±2 85±6 106±7 42±4a 122±6a 165±9
Muscle 2.4±0.2 83±2 84±1 7.1±0.5b 122±4a 130±4 7.2±0.5b 109±7a 116±7
Tumour - - - 1.2±0.07 44±6 45±6 2.28±0.33c 45±6 47±6
ap<0.005 fromcontrols; bp<0.001 from controls;cp<0.01 from MAC13 tumour-bearing animals. dResults are expressed as mean± s.e.m. for
between five and nine separate determinations for the various organ. The rate ofconversion was calculated from the linear part of the curve.
and it appears to be the preferred calorie source in septic
patients with and without cancer (Levinson et al., 1988). We
have previously reported that glucose utilisation by host
organs, particularly the brain, is reduced in the tumour bear-
ing state, to allow high glucose utilisation by the tumour
(Mulligan & Tisdale, 1991a) and the present results confirm
that respiration from glucose is not elevated in animals bear-
ing the MAC tumours. Brain metabolism was maintained by
an increased utilisation of 3-hydroxybutyrate, which is deriv-
ed from lipid metabolism in the liver. This suggests an in-
creased lipid requirement in the tumour-bearing state. We
have simulated the situation after a high fat meal by an oral
load of triolein to cachectic and non-cachectic tumour-bear-
ing animals to investigate alterations in the ability ofthe host
to deal with administered lipid. Previous studies in rats
(Evans & Williamson, 1988a,b; Argiles et al., 1989) have
noted decreased lipid absorption and oxidation by two cyto-
kines interleukin 1 and tumour necrosis factor alpha, while
tumour burden (Walker 256 carcinoma) had no effect on
lipid absorption and decreased oxidation. In the present
study animals bearing the MAC13 tumour resembled more
closely the effect of the cytokines with a slightly decreased
lipid absorption compared with non tumour-bearing animals.
In contrast animals bearing the MAC16 tumour and with
weight loss between 2 and 4 g had a normal lipid absorption,
but an increased oxidation of triolein compared with animals
bearing the MAC13 tumour or non tumour-bearing controls.
This increased utilisation was reflected in a lowered accumu-
lation of ['4C]lipid in heart and adipose tissue, and an in-
creased oxidation of [U'4C]palmitate in fortified homogenates
of liver, heart and skeletal muscle. Despite massive mobilisa-
tion of body fat reserves (Beck & Tisdale, 1987) animals
bearing the MAC16 tumour do not exhibit hypertriglyceri-
demia, and we have recently attributed this to an increase in
the level of lipoprotein lipase in both heart and adiopose
tissue (Briddon et al., 1991). Thus the tissues of cachectic
animals have an increased utilisation of fat as an energy
source, suggesting that the overall energy requirements are
higher in the cachectic state. This increased requirement for
lipid is shown not only by catabolism of adipose tissue, but
also by an increased conversion ofglucose to lipids (Mulligan
& Tisdale, 1991b) and by an increased [14C]lipid accumula-
tion by the MAC16 tumour.
This suggests that fat may be able to overcome some ofthe
metabolic defects seen in cancer cachexia. Animals studies
using a rat model system have shown that hyperalimentation
utilising fat as the primary source of calories generated a
more favourable host: tumour balance, when measured by
the relative rates of growth of each (Buzby et al., 1980).
Intravenous infusion of a commercial triglyceride emulsion to
patients with malignant disease resulted in a decrease in
calorie deficit and a gain in body weight, which correlated
with a gain of intracellular material (Waterhouse & Nye,
1961). Interestingly, the rate of removal of infused lipid from
the blood was increased in patients with malignant disease
paralleling the situation in the mouse model described in the
present study.
The increased lipid oxidation in the cachectic state,
together with the glucose requirement of the tumour, sug-
gests an increased energy requirement, which could be met by
an increased caloric intake. However, since the caloric intake
in animals bearing the MAC16 tumour is not different from
that found in non tumour-bearing controls, the increased
metabolic demand would result in an energy deficiency lead-
ing to progressive weight loss.
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